436 related articles for article (PubMed ID: 32081522)
1. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
[TBL] [Abstract][Full Text] [Related]
3.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
4.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
[TBL] [Abstract][Full Text] [Related]
5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
6. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
[TBL] [Abstract][Full Text] [Related]
7.
Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
[TBL] [Abstract][Full Text] [Related]
8.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
9. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
10. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
12.
Karlowsky JA; Hackel MA; Takemura M; Yamano Y; Echols R; Sahm DF
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0199021. PubMed ID: 34807757
[TBL] [Abstract][Full Text] [Related]
13. Activity of Cefiderocol Against
Iregui A; Khan Z; Landman D; Quale J
Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM; Rizk JG
Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
[TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.
Ito A; Kohira N; Bouchillon SK; West J; Rittenhouse S; Sader HS; Rhomberg PR; Jones RN; Yoshizawa H; Nakamura R; Tsuji M; Yamano Y
J Antimicrob Chemother; 2016 Mar; 71(3):670-7. PubMed ID: 26645269
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany.
Kresken M; Korte-Berwanger M; Gatermann SG; Pfeifer Y; Pfennigwerth N; Seifert H; Werner G
Int J Antimicrob Agents; 2020 Oct; 56(4):106128. PubMed ID: 32758648
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates.
Khanchandani H; Chaudhury M; Rao MS; Ramakrishna N; Venkataramana B; Chaudhury A
Indian J Med Microbiol; 2024; 48():100556. PubMed ID: 38447857
[TBL] [Abstract][Full Text] [Related]
19. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]